NCT04061876[Secondary Source ID] - Search Results

Your saved search

Your RSS Feed

Year	Number of Results
2022	2
2024	1
2025	0

Page 1

Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial.

Dou L, Zhao Y, Yang J, Deng L, Wang N, Zhang X, Liu Q, Yang Y, Wei Z, Wang F, Jiao Y, Li F, Luan S, Hu L, Gao S, Liu C, Liu X, Yan J, Zhang X, Zhou F, Lu P, Liu D. Dou L, et al. Signal Transduct Target Ther. 2024 Oct 23;9(1):288. doi: 10.1038/s41392-024-01987-x. Signal Transduct Target Ther. 2024. PMID: 39438467 Free PMC article. Clinical Trial.

[Kinetics of MDSC in Patients Treated Steroids-Ruxolitinib as the First Line Therapy for aGVHD].

Yang JJ, Peng B, Fang S, Wei Y, Wang H, Zhao YX, Qian K, Wen YN, Liu DH, Dou LP. Yang JJ, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Feb;30(1):276-285. doi: 10.19746/j.cnki.issn.1009-2137.2022.01.046. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022. PMID: 35123640 Clinical Trial. Chinese.

Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.

Dou L, Peng B, Li X, Wang L, Jia M, Xu L, Li F, Liu D. Dou L, et al. Trials. 2022 Jun 6;23(1):470. doi: 10.1186/s13063-022-06426-2. Trials. 2022. PMID: 35668528 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year